Remove 2001 Remove Clinical Research Remove Drug Development Remove Pharmaceuticals
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

Next, Saleko highligts how Northumberland and the North East of the UK are recognised for pharmaceutical manufacturing prowess. From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). billion in funding.

Drugs 189
article thumbnail

Four Pain Models Altasciences Uses to Assess Treatments During Clinical Trials

Alta Sciences

Pain models can be important clinical tools to characterize a novel analgesic, and determine its potential effectiveness in models simulating varying pain stimuli. Here are four main pain models we use to assess treatments in clinical trials: 1. At Altasciences , we have extensive experience testing various pain models.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Chipscreen and HISUN reach a strategic cooperation

The Pharma Data

(hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug. in 19 provinces and regions in China.

article thumbnail

Navigating the Complex Regulatory CRO Landscape for Oncology Trials in the European Union

Conversations in Drug Development Trends

Regulatory Harmonization of Clinical Trials in the EU The EU-CTR repealed the Clinical Trial Directive 2001/20/EC (CTD) and national implementing legislation in the EU Member States on 31 January 2022.

Trials 52
article thumbnail

Human neuronal cells: possibilities in drug safety testing

Drug Target Review

CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact.

Drugs 111